Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Orchard, Paul J  [Clear All Filters]
Journal Article
Chiesa R, Boelens JJan, Duncan CN, Kuehl J-S, Sevin C, Kapoor N, Prasad VK, Lindemans CA, Jones SA, Amartino HM, et al. Variables Affecting Outcomes After Allogeneic Hematopoietic Stem Cell Transplant for Cerebral Adrenoleukodystrophy. Blood Adv. 2021.
Raymond GV, Aubourg P, Paker A, Escolar M, Fischer A, Blanche S, Baruchel A, Dalle J-H, Michel G, Prasad V, et al. Survival and Functional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018.
Gupta A, Downey M, Shanley R, Jennissen C, Miller WP, Lund TC, Orchard PJ, Smith AR. Reduced Toxicity (BuFlu) Conditioning Is Better Tolerated but Has Higher Second Transplant Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders. Biol Blood Marrow Transplant. 2019.
Lund TC, Cathey SS, Miller WP, Eapen M, Andreansky M, Dvorak CC, Davis JH, Dalal JD, Devine SM, Eames GM, et al. Outcomes after Hematopoietic Stem Cell Transplant for Children with I-Cell Disease. Biol Blood Marrow Transplant. 2014.
Lum SHan, Orchard PJ, Lund TC, Miller WP, Boelens JJan, Wynn R. Outcome after a cord blood transplantation using busulfan pharmacokinetic targeted myeloablative conditioning for Hurler syndrome. Biol Blood Marrow Transplant. 2020.
Orchard PJ, Gupta A, Eisengart JB, Polgreen LE, Pollard LM, Braunlin E, Pasquali M, Lund T. Hematopoietic stem cell transplant for Hurler Syndrome: does using bone marrow or umbilical cord blood make a difference?. Blood Adv. 2022.
Polgreen LE, Thomas W, Orchard PJ, Whitley CB, Miller BS. Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2years in children with Hurler or Hunter syndrome. Mol Genet Metab. 2013.
Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy SM, Beitinjaneh A, Boelens JJan, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3(20):3123-3131.